Efficacy of ascorbic acid as adjunctive therapy in the treatment of anemia in chronic renal patients undergoing hemodialysis

Faculdade de Ciências Médicas0 个研究点开始时间: 2020年8月24日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Be part of a hemodialysis program for chronic kidney disease; Be on erythropoietin in any dose, to control anemia of chronic kidney disease; Perform at least three weekly hemodialysis sessions, with a minimum duration of 4 hours each session; Be assiduous at hemodialysis sessions

•Do not use any therapies to control anemia of chronic kidney disease; Be a minor; Chronic ascorbic acid use; Failure of vascular access, such as catheters with low blood flow that prevent hemodialysis with flow above 250 ml / min; Critical worsening of health status, such as prolonged hospitalizations in intensive care units, patients undergoing major surgery with prolonged recovery or patients in palliative care for malignant neoplasms; Little attendance with frequent absences from hemodialysis sessions or undergoing hemodialysis during reduced hours or reduced doses; Any acute or chronic condition that limits the patient's ability to participate in the study, such as advanced heart or liver disease; Have a kidney transplant or recover kidney function in the middle of the study; Malnourished patients, with low body weight, those who use immunosuppressants, chemotherapy, antivirals or immunobiologicals; Patients with a hypersensitivity reaction to some of the research components, such as ascorbic acid or erythropoietin.

发起方

Faculdade de Ciências Médicas